Proteomics International Reports $2.08 Million Quarterly Cash Burn and $3.5 Million Cash Balance

Corporate Streamlining to Support Commercial Strategy

Proteomics International Laboratories (ASX:PIQ) has taken decisive steps to transition from a research-heavy operation to a commercially focused diagnostics company. The recent organisational restructure slashed around 25% of its workforce, equating to nine roles, aiming to deliver over $1 million in annualised savings. This move is designed to conserve cash and sharpen the company's focus on commercial priorities. The restructure also included leadership changes, with Tim Luscombe stepping into the Chief Financial Officer role alongside his Company Secretary duties, and the retirement of long-serving director and chairman Neville Gardner.

Exclusive Distribution Deal with Healius for Promarker Portfolio

Subsequent to the quarter, Proteomics International secured a national distribution agreement with Healius Limited, appointing the pathology giant as the exclusive Australian distributor for its Promarker® diagnostic tests. The initial three-year contract, with a mutual option to extend for another three years, leverages Healius's extensive network of over 2,000 patient collection centres. Proteomics will retain responsibility for laboratory testing and clinical reporting, while Healius will manage specimen collection, distribution, and market access. The phased commercial rollout is planned for FY27 following integration of operations and IT systems. Given the early commercial stage of the Promarker portfolio, revenue forecasts remain uncertain. This deal marks a significant step in Proteomics' distributor-led commercialisation approach, which has been evolving since the strategic pivot announced earlier this yearexclusive three-year distribution agreement.

Strengthened Intellectual Property with US Patent for Endometriosis Test

The United States Patent and Trademark Office granted Proteomics International Patent No. 12674806 covering its PromarkerEndo technology for diagnosing endometriosis through blood-based protein biomarkers. This patent, which extends protection until March 2041 subject to maintenance, enhances the company's IP position in the lucrative US healthcare market. The technology promises earlier and more precise diagnosis of endometriosis, a condition notoriously difficult to detect. The patent follows prior grants in Japan, with applications ongoing in other key jurisdictions. This development bolsters the commercial and licensing prospects of PromarkerEndo as Proteomics pursues global market penetrationUS patent granted for PromarkerEndo.

Ongoing Product Development and Strategic Review

During the quarter, Proteomics continued refining its Promarker assays, including PromarkerEso and PromarkerEndo, focusing on validation and streamlined laboratory protocols. The company also published a US health economics manuscript for PromarkerD in PharmacoEconomics, supporting reimbursement readiness. Meanwhile, a strategic review of the OxiDx business unit has commenced to explore development, partnerships, licensing, and other options. Investment decisions will hinge on commercial potential and alignment with Proteomics' strategic priorities.

Financial Position and Cash Flow Considerations

Proteomics ended the June quarter with $3.5 million in cash and equivalents, down from $5.69 million at March 31. Operating cash outflows totalled $2.08 million, which included a $0.46 million one-off cost for redundancy payments linked to the restructure. Staff and corporate costs accounted for $1.09 million, research and development $0.87 million, and product-related expenses $0.29 million. The company estimates it has approximately 1.7 quarters of funding available based on current burn rates, though this figure excludes the non-recurring redundancy costs and anticipates a forthcoming R&D tax incentive refund in the first half of FY27. Proteomics is actively evaluating funding options to support ongoing operations and strategic initiatives.